Novartis Ag (NVS) Receivables - Other (2017 - 2025)
Novartis Ag (NVS) has disclosed Receivables - Other for 9 consecutive years, with $1.1 billion as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 4.01% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 4.01% year-over-year, with the annual reading at $1.1 billion for FY2025, 4.01% up from the prior year.
- Receivables - Other hit $1.1 billion in Q4 2025 for Novartis Ag, up from $1.1 billion in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.3 billion in Q4 2023 to a low of $793.0 million in Q4 2021.
- Historically, Receivables - Other has averaged $1.0 billion across 5 years, with a median of $1.1 billion in 2024.
- Biggest five-year swings in Receivables - Other: decreased 17.65% in 2021 and later surged 30.69% in 2023.
- Year by year, Receivables - Other stood at $793.0 million in 2021, then grew by 20.81% to $958.0 million in 2022, then soared by 30.69% to $1.3 billion in 2023, then fell by 12.38% to $1.1 billion in 2024, then rose by 4.01% to $1.1 billion in 2025.
- Business Quant data shows Receivables - Other for NVS at $1.1 billion in Q4 2025, $1.1 billion in Q4 2024, and $1.3 billion in Q4 2023.